Vanderbilt University Medical Center, Division of Hematology Oncology, Nashville, TN, USA.
Thoracic Oncology Unit, Medical Oncology Department, Fondazione IRCCS Instituto Nazionale dei Tumori, Milan, Italy.
Nat Rev Clin Oncol. 2021 Jan;18(1):1-2. doi: 10.1038/s41571-020-00441-5.
The coronavirus disease 2019 (COVID-19) pandemic has disrupted health care worldwide. Patients with cancer seem to be particularly susceptible to morbidities and mortality from this novel disease. No COVID-19-specific therapy currently seems to offer a survival benefit to this unique patient population. Furthermore, the global effects on routine cancer care will likely be felt for decades to come.
2019 年冠状病毒病（COVID-19）大流行扰乱了全球的医疗保健服务。癌症患者似乎特别容易受到这种新型疾病的发病率和死亡率的影响。目前，尚无 COVID-19 特异性疗法似乎为这一独特的患者群体带来生存获益。此外，COVID-19 对常规癌症护理的全球影响可能在未来几十年内持续存在。
